Tempest Therapeutics, Inc. Write off of Deferred Debt Issuance Cost
Tempest Therapeutics, Inc. (TPST) reported Write off of Deferred Debt Issuance Cost of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:WriteOffOfDeferredDebtIssuanceCost · last filed 2020-03-11
- Tempest Therapeutics, Inc. write off of deferred debt issuance cost for the quarter ending 2018-12-31 was $0.00.
- Tempest Therapeutics, Inc. write off of deferred debt issuance cost for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- Tempest Therapeutics, Inc. write off of deferred debt issuance cost for fiscal 2018 was $871.00K, a 36.14% decline from fiscal 2017.
- Tempest Therapeutics, Inc. write off of deferred debt issuance cost for fiscal 2017 was $1.36M.
| Period end | Write off of Deferred Debt Issuance Cost 3 month | Write off of Deferred Debt Issuance Cost 9 month | Write off of Deferred Debt Issuance Cost 12 month |
|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-11 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $871.00K 10-K · filed 2020-03-11 | |
| 2018-09-30 | $871.00K 10-Q · filed 2019-11-13 | ||
| 2017-12-31 | $1.36M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |